Discovery of U2AF1 neoantigens in myeloid neoplasms
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-007490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Melinda Ann Biernacki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA mbiernac@fredhutch.org. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Gerdin Family Endowed Chair for Leukemia Research, Fred Hutch, Be The Match Foundation.
Abstract (Originalsprache)
Background
Myelodysplastic syndromes (MDS) arise from somatic mutations acquired in hematopoietic stem and progenitor cells, causing cytopenias and predisposing to transformation into secondary acute myeloid leukemia (sAML). Recurrent mutations in spliceosome genes, including U2AF1 , are attractive therapeutic targets as they are prevalent in MDS and sAML, arise early in neoplastic cells, and are generally absent from normal cells, including normal hematopoietic cells. MDS and sAML are susceptible to T cell-mediated killing, and thus engineered T-cell immunotherapies hold promise for their treatment. We hypothesized that targeting spliceosome mutation-derived neoantigens with transgenic T-cell receptor (TCR) T cells would selectively eradicate malignant cells in MDS and sAML.
Methods
We identified candidate neoantigen epitopes from recurrent protein-coding mutations in the spliceosome genes SRSF2 and U2AF1 using a multistep in silico process. Candidate epitopes predicted to bind human leukocyte antigen (HLA) class I, be processed and presented from the parent protein, and not to be subject to tolerance then underwent in vitro immunogenicity screening. CD8 + T cells recognizing immunogenic neoantigen epitopes were evaluated in in vitro assays to assess functional avidity, confirm the predicted HLA restriction, the potential for recognition of similar peptides, and the ability to kill neoplastic cells in an antigen-specific manner. Neoantigen-specific TCR were sequenced, cloned into lentiviral vectors, and transduced into third-party T cells after knock-out of endogenous TCR, then tested in vitro for specificity and ability to kill neoplastic myeloid cells presenting the neoantigen. The efficacy of neoantigen-specific T cells was evaluated in vivo in a murine cell line-derived xenograft model.
Results
We identified two neoantigens created from a recurrent mutation in U2AF1 , isolated CD8 + T cells specific for the neoantigens, and demonstrated that transferring their TCR to third-party CD8 + T cells is feasible and confers specificity for the U2AF1 neoantigens. Finally, we showed that these neoantigen-specific TCR-T cells do not recognize normal hematopoietic cells but efficiently kill malignant myeloid cells bearing the specific U2AF1 mutation, including primary cells, in vitro and in vivo.
Conclusions
These data serve as proof-of-concept for developing precision medicine approaches that use neoantigen-directed T-cell receptor-transduced T cells to treat MDS and sAML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA mbiernac@fredhutch.org.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
- Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Immunology, University of Washington, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Department of Pediatrics, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Melinda Ann Biernacki
Förderung
- NCI NIH HHS
- Gerdin Family Endowed Chair for Leukemia Research, Fred Hutch
- Be The Match Foundation
- National Cancer Institute
- MPN Research Foundation
Zitieren
APA
Biernacki, M. A., Lok, J., Black, R. G., Foster, K. A., Cummings, C., Woodward, K. B., Monahan, T., Oehler, V. G., Stirewalt, D. L., Wu, D., Rongvaux, A., Deeg, H. J., & Bleakley, M. (2023). Discovery of U2AF1 neoantigens in myeloid neoplasms. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007490
Vancouver
Biernacki MA, Lok J, Black RG, Foster KA, Cummings C, Woodward KB, et al. Discovery of U2AF1 neoantigens in myeloid neoplasms. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-007490
BibTeX
@article{Biernacki2023,
author = {Biernacki, Melinda Ann and Lok, Jessica and Black, Ralph Graeme and Foster, Kimberly A and Cummings, Carrie and Woodward, Kyle B and Monahan, Tim and Oehler, Vivian G and Stirewalt, Derek L and Wu, David and Rongvaux, Anthony and Deeg, Hans Joachim and Bleakley, Marie},
title = {Discovery of U2AF1 neoantigens in myeloid neoplasms},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-007490}
}
EUVIMED